Propensity score-matched comparison with non-cancer control
| Factor | PD-1B+ /vac+ | Healthy control | P value | PD-1B-/vac+ | Healthy control | P value | |
| Age, mean (SD) | 51.17 (10.42) | 50.08 (11.65) | 0.20 | 49.93 (10.37) | 48.04 (11.69) | 0.09 | |
| Gender | Male | 34 (24.6%) | 38 (27.5%) | 0.58 | 43 (26.5%) | 42 (25.9%) | 0.90 |
| Female | 104 (75.4%) | 100 (72.5%) | 119 (73.5%) | 120 (74.1%) | |||
| Dose of vaccine | 1 | 58 (42.0%) | 63 (45.7%) | 0.54 | 90 (55.6%) | 83 (51.2%) | 0.44 |
| 2 | 80 (58.0%) | 75 (54.3%) | 72 (44.4%) | 79 (48.8%) | |||
| Comorbidity with rheumatic disease | Yes | 32 (23.2%) | 29 (21.0%) | 0.66 | 38 (23.5%) | 36 (22.2%) | 0.79 |
| No | 106 (76.8%) | 109 (79.0%) | 124 (76.5%) | 126 (77.8%) | |||
| Fatigue | Yes | 20 (14.5%) | 17 (12.3%) | 0.60 | 27 (16.7%) | 18 (11.1%) | 0.15 |
| No | 118 (85.5%) | 121 (87.7%) | 135 (83.3%) | 144 (88.9%) | |||
| Fever | Yes | 12 (8.7%) | 21 (15.2%) | 0.10 | 12 (7.4%) | 22 (13.6%) | 0.07 |
| No | 126 (91.3%) | 117 (84.8%) | 150 (92.6%) | 140 (86.4%) | |||
| Lymphadenopathy | Yes | 15 (10.9%) | 23 (16.7%) | 0.16 | 19 (11.7%) | 30 (18.5%) | 0.09 |
| No | 123 (89.1%) | 115 (83.3%) | 143 (88.3%) | 132 (81.5%) | |||
| Nausea | Yes | 15 (10.9%) | 23 (16.7%) | 0.16 | 18 (11.1%) | 25 (15.4%) | 0.25 |
| No | 123 (89.1%) | 115 (83.3%) | 144 (88.9%) | 137 (84.6%) | |||
| Headache | Yes | 13 (9.4%) | 8 (5.8%) | 0.26 | 13 (8%) | 10 (6.2%) | 0.52 |
| No | 125 (90.6%) | 130 (94.2%) | 149 (92.0%) | 152 (93.8%) | |||
| Serocoversion | Positive | 94 (68.1%) | 111 (80.4%) | 0.02 | 116 (%) | 135 (%) | 0.01 |
| Negative | 44 (31.9%) | 27 (19.6%) | 46 (%) | 27 (%) | |||
| Rash | Yes | 35 (25.4%) | 12 (8.7%) | <0.01 | 10 (6.2%) | 14 (8.6%) | 0.40 |
| No | 103 (74.6%) | 126 (91.3%) | 152 (93.8%) | 148 (91.4%) | |||
| Arthralgia | Yes | 19 (13.8%) | 10 (7.2%) | 0.08 | 18 (11.1%) | 12 (7.4%) | 0.27 |
| No | 119 (86.2%) | 128 (92.8%) | 144 (88.9%) | 150 (92.6%) | |||
PD-1B, progression cell death blockers; SD, standard deviation.